Please assess the completion status of the following clinical trial:

Trial Title: Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Age 60 years or older~* Measurable non-metastatic and non-inflammatory breast cancer~* Tumor of 2 cm or larger~* ER and/or PgR positive tumor~* Co-morbidity index 0 - 3, e.g., no other serious medical condition~Exclusion Criteria:~* Prior medical therapy for a malignant disease, including aromatase inhibitors~* Distant metastasis~* Need for chemotherapy~* Past or current history of other neoplasms (except for curative treated basal skin cancer or in situ carcinoma of the cervix uteri)~* Treatment with a non-approved drug within 30 days

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Postoperative letrozole (Type: ACTIVE_COMPARATOR): Definitive surgery without preoperative AI treatment
- Preoperative letrozole (Type: EXPERIMENTAL): Treatment with letrozole for 4 months before definitive surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).